Hereditary Breast and Ovarian Cancer Panel, Sequencing and Deletion/Duplication

2012026
copy
 

Copy Utility


emailprint
Example Reports
Negative
Positive
COMPONENT DESCRIPTION TEST TYPE INFECTIOUS UNIT OF MEASURE NUMERIC MAP LOINC
2012029
Breast/Ovarian Cancer Panel Spcm
PROMPT
N
31208-2
2012028
Breast/Ovarian Cancer Panel Interp
Resultable
N
35474-6

For questions regarding the Interface Map, please contact interface.support@aruplab.com.


Download to Excel

Icon

Supplemental Resources

Icon

Patient History for Hereditary Breast and Ovarian Cancer Syndrome (HBOC)

Icon

Additional Technical Information
Ordering Recommendation

Recommended test to confirm a diagnosis of hereditary breast and/or ovarian cancer in individuals with a personal or family history of breast and/or ovarian cancer. When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).

Mnemonic
BOCAPAN
Methodology

Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Performed

Varies

Reported

3-6 weeks

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA) or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions
Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note

Genes tested: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2*, DICER1, EPCAM****, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1**, PALB2, PMS2, PTEN, RAD51C, RAD51D, RECQL***, STK11, TP53
 
* One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
** Deletion/duplication detection is not available for this gene.
*** One or more exons are not covered by sequencing, and deletion/duplication detection is not available for this gene; see Additional Technical Information.
**** Deletion/duplication only; sequencing is not available for this gene.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
11/12/2018
X
X
N/A
CPT Codes

81432; 81433

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2012028 Breast/Ovarian Cancer Panel Interp 35474-6
2012029 Breast/Ovarian Cancer Panel Spcm 31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Cowden syndrome
  • EPCAM deletions only
  • HBOC syndrome
  • Hereditary Diffuse Gastric Cancer (HDGC)
  • Li-Fraumeni syndrome (LFS)
  • Lynch syndrome
  • MUTYH-Associated Polyposis (MAP)
  • Neurofibromatosis Type 1 (NF1)
  • Peutz-Jegher syndrome (PJS)
  • PTEN Hamaratoma Tumor syndrome
Hereditary Breast and Ovarian Cancer Panel, Sequencing and Deletion/Duplication